97 related articles for article (PubMed ID: 25656129)
1. [Screening for predictive biomarkers of bevacizumab treatment in gastric cancer subcutaneous xenografts].
Zhang Q; Xu J; Ye J; Yuan Y; Chen J; Peng J; He Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Feb; 18(2):177-80. PubMed ID: 25656129
[TBL] [Abstract][Full Text] [Related]
2. [Impacts of Bevacizumab on vascular endothelial growth factor and Sp1 expression in gastric cancer xenografts].
Zhou CF; Ji J; Yuan F; Yu YY; Liu BY; Zhang J; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):180-4. PubMed ID: 22368029
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
5. [Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
Fan YZ; Chen CQ; Zhao ZM; Sun W
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):693-9. PubMed ID: 16681930
[TBL] [Abstract][Full Text] [Related]
6. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
7. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
8. [Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles].
Huang KH; Liu JH; Wang LY; Zhu ZH; Chen QK; Min J; Chen RF
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):482-5. PubMed ID: 17851795
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effects of luteolin on human gastric carcinoma xenografts in nude mice and its mechanism].
Lu XY; Li YH; Xiao XW; Li XB
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):142-6. PubMed ID: 23648354
[TBL] [Abstract][Full Text] [Related]
10. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
15. [Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
Huang HW; Chen P; Li BZ; Fu JX; Li J; Zhang XH; Liu R; Fan YY; Zhang H; Chow HC; Leung AY; Liang R
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):652-7. PubMed ID: 23159076
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
Fan YF; Huang ZH; Nie J
Ai Zheng; 2002 Dec; 21(12):1319-23. PubMed ID: 12520739
[TBL] [Abstract][Full Text] [Related]
17. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
[TBL] [Abstract][Full Text] [Related]
19. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
20. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor].
Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
